How many syringe units is a retatrutide dose?

It depends on the concentration, which is set by your vial size and how much water you added. Enter both in the calculator and every step of the schedule gets a unit mark at once. Because the doses here are whole milligrams rather than micrograms, a vial sized for a microgram-dosed peptide cannot hold a single dose, which the vial presets account for.

Why does this page show a schedule instead of a dose range?

Because a titration schedule is not a range with a point inside it. It is a sequence, and the sequence is the dose. Klarovel keeps dose data in more than one place, and for this class the published titration schedule outranks the engine's experience-tier table by an explicit written precedence rule. Publishing an envelope beside a schedule would invite the exact thing the schedule exists to prevent, which is starting somewhere in the middle.

What happens if a step is not tolerated?

The schedule holds rather than advances, for a stated number of additional weeks, and then drops back one step for a bounded period before re-attempting. Both figures are shown on this page and both are read from the engine's titration constant. Reaching maintenance therefore takes longer than the headline figure whenever a step is held, which is the normal case rather than the exception.

Is retatrutide approved?

No. It is investigational, with a registered phase 3 programme rather than a marketing authorisation. Stating that is reporting, not a warning: the phase 2 results are among the largest weight changes published for any single agent, and the phase 3 trials that would settle the question are registered and under way. Both halves of that are true at the same time.

Does retatrutide need to be cycled?

No, and this is one of the few places the engine treats a class differently from the rest of the catalog. Compounds in this class are marked continuous use: there is no off-period, because stopping reverses the effect. The supplies table on this page therefore counts weeks to maintenance rather than a cycle length.

When is retatrutide not appropriate?

The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound and its class, with the engine's own stated reason and the severity. A public page cannot know your health data, so it names what would change the answer.

Where do the numbers on this page come from?

The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this peptide?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Retatrutide dosage calculator

Retatrutide is dosed from a titration schedule, not from a range. This calculator gives the syringe units for every step of that schedule at your vial size and water volume, and shows the week each step opens.

Below the calculator: the full titration schedule, a reconstitution chart built from its steps, the supplies it takes to reach maintenance, the health conditions that change the answer, and the references. Every dose figure is read from the Klarovel engine's own titration constant, never typed into the page.

How many milligrams are in your Retatrutide vial?

How much bacteriostatic water are you adding?

Syringe size

Which step of the titration are you on?

Each chip is a rung on the published titration schedule, in the order it is climbed. The full schedule with the week each rung opens is below.

No experience, weight or age input here

Retatrutide is dosed from a titration schedule rather than an experience envelope, and the schedule is not individualised by age, sex, body mass, kidney function or liver function. The other calculators on this site offer those inputs because the compounds they cover genuinely use them. Offering them here would imply a personalisation the published schedule does not have.

Step 1 dose, from week 1

20.0 units

2 mg

Concentration: 10 mg/ml
Injection volume: 0.2 ml
Doses per vial: 10

Frequency: once weekly. Timing: Any time. Route: subcutaneous.

Schedule note: Investigational. Dosing per the phase 2 trial protocol.

The retatrutide titration schedule, at your mix

Every rung of the published schedule, the week it opens, and the unit mark it works out to at 20 mg in 2 ml. Change the vial or the water above and the whole table recomputes. The schedule itself does not change: it is the same for every reader, which is the point of a titration ladder.

Titration schedule with dose and syringe units per step
Step	Opens	Dose	Draw	Doses per vial
Step 1	Week 1-4	2 mg	20.0 units	10
Step 2	Week 5-8	4 mg	40.0 units	5
Step 3	Week 9-12	8 mg	80.0 units	2
Maintenance	Week 13 onward	12 mg	120.0 units	1

If a rung is not tolerated the schedule holds it for a further 4 weeks rather than advancing. If it is still not tolerated after that, the schedule drops back one rung for up to 4 weeks before re-attempting. Reaching maintenance takes 12 weeks when every rung is tolerated first time, and longer when one is not.

Rungs, durations and tolerance rules read verbatim from GLP1_TITRATION_LADDERS, the engine's label-driven titration constant. ADR-046 puts that ahead of the engine's experience-tier dose table for this class, so the tier envelope is deliberately not published on this page: two dose stories on one page is worse than one. Unit marks are arithmetic over your vial size and water volume.

Retatrutide reconstitution chart

Pre-calculated syringe units for every water volume against the dose figures this compound actually uses, at your selected vial size of 20 mg. A cell reading "n/a" means the draw exceeds a 100-unit syringe at that concentration.

Syringe units per water volume for each sourced dose figure
BAC water	Conc.	Step 12 mg	Step 24 mg	Step 38 mg	Maintenance12 mg
1 ml	20 mg/ml	10	20	40	60
1.5 ml	13.33 mg/ml	15	30	60	90
2 ml	10 mg/ml	20	40	80	n/a
2.5 ml	8 mg/ml	25	50	100	n/a
3 ml	6.67 mg/ml	30	60	n/a	n/a
4 ml	5 mg/ml	40	80	n/a	n/a
5 ml	4 mg/ml	50	100	n/a	n/a

Column doses are the rungs of the titration schedule in GLP1_TITRATION_LADDERS. Unit marks are arithmetic.

Supplies to reach maintenance

Climbing every rung without a hold takes 12 weeks at one administration per week. Multiplied out at your selected step and your mix, that is what reaching maintenance costs in consumables. A held or dropped-back rung lengthens it, and the schedule has no off-period to end on: the engine catalog marks this compound continuous use.

Bacteriostatic water bottle size

Supplies for one on-cycle
Weeks to maintenance	12 weeks, no off-period
Administrations per week	1
Total administrations	12
Vials of 20 mg	2
Insulin syringes	12 (30-unit holds the draw)
Bacteriostatic water	4 ml, 1 bottle of 10 ml

Weeks to maintenance and the weekly cadence read from GLP1_TITRATION_LADDERS. Continuous use read from PEPTIDE_CATALOG. Counts are arithmetic.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

About Retatrutide

Retatrutide, developed as LY3437943, is a single molecule that agonises three receptors at once: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide 1 receptor and the glucagon receptor. The third is what separates it from semaglutide and tirzepatide, and a 2024 structural study in Cell Discovery mapped how one peptide manages all three. It is investigational. It is not approved by the FDA, and the dose figures on this page come from a trial protocol rather than from a label.

The phase 2 obesity trial, published in the New England Journal of Medicine in 2023 and registered as NCT04881760, is the study most readers are thinking of. At forty-eight weeks the least-squares mean change in body weight was 24.2 per cent below baseline in the highest dose group, against 2.1 per cent in the placebo group. A phase 2 trial in type 2 diabetes appeared in the Lancet the same year, and a randomised trial in metabolic dysfunction-associated steatotic liver disease in Nature Medicine the year after.

The phase 3 programme is registered and running. TRIUMPH-1 through TRIUMPH-4 (NCT05929066, NCT05929079, NCT05882045 and NCT05931367) have completed, and further TRIUMPH trials remain active. That is the honest state of the evidence: a large, well-registered programme that has not yet produced an approval, which is a different thing from either a proven drug or an unstudied one.

Administration and cycling

Administration and cycling reference
Route	subcutaneous
Timing	Any time
Catalog frequency	once weekly
Cycle	52 weeks on, 0 weeks off
Taper before the off period	Not specified
Loading phase	None
Weight sensitive	No

Catalog note: Triple agonist at the GIP, GLP-1 and glucagon receptors. Dosing follows the phase 2 trial protocol. Not FDA-approved, and requires experienced guidance.

Every row above is read from PEPTIDE_CATALOG, the engine catalog, and the note is quoted verbatim rather than paraphrased.

Why this page shows a schedule and not a dose range

Klarovel holds dose data for Retatrutide in more than one place, and they do not all say the same thing. The engine's experience-tier dose table carries a span per experience level. The older research row carries a single conservative figure. The titration schedule carries a fixed sequence of rungs with a duration on each.

For this class the schedule is the one that binds, and that precedence is written down rather than improvised: it is the first rule in the source order the dosing hub, the dose guard and the engine all follow. The reason is that a titration schedule is not a range someone picks a point inside. It is a sequence, and the sequence is the dose. Publishing an experience envelope next to it would invite exactly the thing the schedule exists to prevent, which is starting somewhere in the middle.

So the experience-level, body-weight and age inputs the other calculators on this site offer are absent here. They are absent because the published schedule is not adjusted for any of them, not because the page ran out of room.

When this would not be recommended for you

A public page cannot know your health data, so it cannot tell you whether a compound is appropriate. What it can do is list the conditions the engine's contraindication matrix associates with this compound, and what the engine does about each. In a generated protocol these resolve automatically and the reason is shown alongside the exclusion.

Health conditions and the engine's action
Condition	Engine action	Reason
Diabetes type1	Caution	GLP-1 agonists affect insulin secretion and require careful adjustment of insulin doses with type 1 diabetes. Only under diabetologist supervision.
Kidney	Monitored	GLP-1 agonists may affect kidney function. Monitor eGFR and creatinine with existing kidney disease.
Liver	Monitored	GLP-1 agonists are partially hepatically metabolized. Monitor ALT/AST with liver disease. Tesamorelin may actually improve liver fat.

Conditions, severities and reasons read verbatim from CONTRAINDICATION_RULES, the engine's contraindication matrix. This is not the full set of things worth raising with a clinician; it is the set the engine acts on.

Questions

How many syringe units is a retatrutide dose?: It depends on the concentration, which is set by your vial size and how much water you added. Enter both in the calculator and every step of the schedule gets a unit mark at once. Because the doses here are whole milligrams rather than micrograms, a vial sized for a microgram-dosed peptide cannot hold a single dose, which the vial presets account for.
Why does this page show a schedule instead of a dose range?: Because a titration schedule is not a range with a point inside it. It is a sequence, and the sequence is the dose. Klarovel keeps dose data in more than one place, and for this class the published titration schedule outranks the engine's experience-tier table by an explicit written precedence rule. Publishing an envelope beside a schedule would invite the exact thing the schedule exists to prevent, which is starting somewhere in the middle.
Why is there no experience level, weight or age input?: Because the published schedule is not adjusted for any of them. The other calculators on this site offer those inputs because the compounds they cover genuinely use them. Offering controls here that silently changed nothing would imply a personalisation that does not exist.
What happens if a step is not tolerated?: The schedule holds rather than advances, for a stated number of additional weeks, and then drops back one step for a bounded period before re-attempting. Both figures are shown on this page and both are read from the engine's titration constant. Reaching maintenance therefore takes longer than the headline figure whenever a step is held, which is the normal case rather than the exception.
Is retatrutide approved?: No. It is investigational, with a registered phase 3 programme rather than a marketing authorisation. Stating that is reporting, not a warning: the phase 2 results are among the largest weight changes published for any single agent, and the phase 3 trials that would settle the question are registered and under way. Both halves of that are true at the same time.
Does retatrutide need to be cycled?: No, and this is one of the few places the engine treats a class differently from the rest of the catalog. Compounds in this class are marked continuous use: there is no off-period, because stopping reverses the effect. The supplies table on this page therefore counts weeks to maintenance rather than a cycle length.
When is retatrutide not appropriate?: The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound and its class, with the engine's own stated reason and the severity. A public page cannot know your health data, so it names what would change the answer.
Where do the numbers on this page come from?: The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this peptide?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other peptide calculators

References

These papers cover retatrutide from receptor pharmacology through the phase 2 programme: the structural work on triple agonism, the phase 2 obesity and type 2 diabetes trials, the steatotic liver disease trial, body composition substudies, and the systematic reviews and meta-analyses of the trials to date. They are not the source of the dose figures on this page, which come from the engine's titration constant.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

12 references, every identifier resolved against NCBI on 2026-08-03. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query). Regenerated 2026-08-03 for cjc1295_no_dac, ipamorelin, pt141, retatrutide, aod9604 and sermorelin using the same esearch + esummary procedure; no record was added whose esummary payload lacked a title, journal or first author.

1.Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023. PMID 37366315
2.Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023. PMID 37385280
3.Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 2024. PMID 38858523 PMC11271400
4.Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol 2025. PMID 40609566
5.Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 2026. PMID 42250575
6.Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 2026. PMID 41090431 PMC12673447
7.Li W et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov 2024. PMID 39019866 PMC11255275
8.Pasqualotto E et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open 2024. PMID 39318607 PMC11420505
9.Misra S et al. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. J Basic Clin Physiol Pharmacol 2025. PMID 40728138
10.Kaur M et al. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol 2024. PMID 38367045
11.Katsi V et al. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules 2025. PMID 40563436 PMC12190491
12.Drucker DJ et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care 2024. PMID 38843460

Beyond the arithmetic

Your health data, your protocol.

A calculator converts a dose into syringe units. The Klarovel engine decides the dose: it reads your health data, resolves contraindications, sets the envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.